Q3 2016 13F Holders as of 9/30/2016
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
164
-
Total 13F shares, excl. options
-
39.5M
-
Shares change
-
+2.56M
-
Total reported value, excl. options
-
$2.8B
-
Value change
-
+$185M
-
Put/Call ratio
-
0.45
-
Number of buys
-
88
-
Number of sells
-
-69
-
Price
-
$70.94
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q3 2016
193 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q3 2016.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 164 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39.5M shares
of 96M outstanding shares and own 41.15% of the company stock.
Largest 10 shareholders include FMR LLC (5.91M shares), Capital Research Global Investors (4.83M shares), WELLINGTON MANAGEMENT GROUP LLP (4.13M shares), VANGUARD GROUP INC (2.66M shares), PRICE T ROWE ASSOCIATES INC /MD/ (1.83M shares), STATE STREET CORP (1.48M shares), BlackRock Fund Advisors (1.47M shares), COLUMBIA WANGER ASSET MANAGEMENT LLC (1.26M shares), BlackRock Institutional Trust Company, N.A. (908K shares), and WELLS FARGO & COMPANY/MN (736K shares).
This table shows the top 164 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.